ATE279446T1 - Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen - Google Patents

Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen

Info

Publication number
ATE279446T1
ATE279446T1 AT00922751T AT00922751T ATE279446T1 AT E279446 T1 ATE279446 T1 AT E279446T1 AT 00922751 T AT00922751 T AT 00922751T AT 00922751 T AT00922751 T AT 00922751T AT E279446 T1 ATE279446 T1 AT E279446T1
Authority
AT
Austria
Prior art keywords
dissolving
production
hydrophobic compounds
structured systems
amphiphilic cyclodextrins
Prior art date
Application number
AT00922751T
Other languages
German (de)
English (en)
Inventor
Rachel Auzely-Velty
Bruno Perly
Florence Djedaini-Pilard
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of ATE279446T1 publication Critical patent/ATE279446T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Optics & Photonics (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
AT00922751T 1999-04-29 2000-04-26 Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen ATE279446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905460A FR2792942B1 (fr) 1999-04-29 1999-04-29 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
PCT/FR2000/001102 WO2000066635A1 (fr) 1999-04-29 2000-04-26 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes

Publications (1)

Publication Number Publication Date
ATE279446T1 true ATE279446T1 (de) 2004-10-15

Family

ID=9545038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922751T ATE279446T1 (de) 1999-04-29 2000-04-26 Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen

Country Status (7)

Country Link
US (1) US6858723B1 (enExample)
EP (1) EP1177217B1 (enExample)
JP (1) JP4698842B2 (enExample)
AT (1) ATE279446T1 (enExample)
DE (1) DE60014885T2 (enExample)
FR (1) FR2792942B1 (enExample)
WO (1) WO2000066635A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1543841A4 (en) * 2002-08-15 2011-03-16 Yunqing Liu SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
FR2850972B1 (fr) * 2003-02-07 2005-03-11 Commissariat Energie Atomique Derives de per(3,6-anhydro) cyclodextrines, leur preparation et leur utilisation pour vehiculer des elements metalliques vers des cibles biologiques ou pour decontaminer des cibles ou fluides biologiques
FR2861396B1 (fr) 2003-10-24 2005-12-16 Commissariat Energie Atomique Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations
BRPI0417593A (pt) * 2003-12-18 2007-03-20 Ciba Sc Holding Ag derivados de polissacarìdeo reativo, sua preparação e seu uso
WO2006001844A2 (en) * 2004-01-29 2006-01-05 Pinnacle Pharmaceuticals β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN
EP1846006A4 (en) * 2005-01-28 2011-04-20 Pinnacle Pharmaceuticals Inc BETA-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS
EP2023896B8 (en) 2006-05-19 2016-09-14 Viroblock SA A composition for inactivating an enveloped virus
FR2907455A1 (fr) * 2006-10-18 2008-04-25 Commissariat Energie Atomique Oligosaccharides cycliques,notamment derives de cyclodextrines amphiphiles,substitues par un ou plusieurs groupements polycycles naturels,tels que les triterpenoides.
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
FR2919872B1 (fr) * 2007-08-10 2009-12-18 Commissariat Energie Atomique Derives de cyclodextrines
JP5364923B2 (ja) * 2009-01-28 2013-12-11 学校法人福岡大学 多機能性シクロデキストリン誘導体、その包接化合物およびそれらの製造方法。
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014058438A1 (en) * 2012-10-12 2014-04-17 Empire Technology Development Llc Paints and coatings containing cyclodextrin additives
CN105392804B (zh) 2013-08-09 2018-07-10 生物辐射实验室股份有限公司 采用修饰的环糊精的蛋白质检测
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
US20220362401A1 (en) * 2019-09-20 2022-11-17 The University Of Kitakyushu Particles, method for producing particles, drug, method for producing drug, and anti-cancer agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681868A1 (fr) * 1991-09-30 1993-04-02 Sederma Sa Nouvelles substances amphiphiles derivees de cyclodextrines et leur utilisation dans des compositions cosmetiques.
FR2726765B1 (fr) 1994-11-14 1996-12-20 Cis Bio Int Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene
FR2736056B1 (fr) * 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
AU2002241823A1 (en) * 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials

Also Published As

Publication number Publication date
DE60014885D1 (de) 2004-11-18
JP2002543249A (ja) 2002-12-17
US6858723B1 (en) 2005-02-22
DE60014885T2 (de) 2005-10-27
EP1177217A1 (fr) 2002-02-06
WO2000066635A1 (fr) 2000-11-09
FR2792942A1 (fr) 2000-11-03
EP1177217B1 (fr) 2004-10-13
FR2792942B1 (fr) 2001-06-08
JP4698842B2 (ja) 2011-06-08

Similar Documents

Publication Publication Date Title
ATE279446T1 (de) Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen
Aiassa et al. Cyclodextrins and their derivatives as drug stability modifiers
Okimoto et al. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins
Rub et al. Interaction of cationic amphiphilic drug nortriptyline hydrochloride with TX-100 in aqueous and urea solutions and the studies of physicochemical parameters of the mixed micelles
Zia et al. Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE) 7M-β-CD to HP-β-CD
Qiu et al. Spiropyran-linked dipeptide forms supramolecular hydrogel with dual responses to light and to ligand–receptor interaction
Ji et al. Regulating Higher‐Order Organization through the Synergy of Two Self‐Sorted Assemblies
DE60225571D1 (de) Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen
ES2119496T3 (es) Composicion de polvo de polimero redispersable que contiene ciclodextrinas o derivados de ciclodextrina.
ATE340825T1 (de) Ternäre mischungen von bioabbaubaren polyestern und daraus hergestellten produkten
ATE243688T1 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE50210313D1 (de) Amphotere sterole und deren verwendung
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
Piel et al. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins
HUP9701945A1 (hu) Ciklodextrint és taxánszármazékot tartalmazó injekciós gyógyszerkészítmény
AR024812A1 (es) Composiciones para el tratamiento del mal olor y metodo para reducir el mismo.
DE69728783D1 (de) Verbesserte arzneimittel
BRPI0503828A (pt) formulações contendo pó, aquosas, lìquidas, não alcoólicas
Maeda et al. Inclusion complexes of melatonin with modified cyclodextrins
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
NO20070669L (no) Fremgangsmate for fremstillingen av en prioksikam: betacyklodekstrininklusjonsforbindelse
EP0788373B1 (en) Novel complexes of taxol or taxotere and pharmaceutical compositions
Ol’khovich et al. Inclusion complexes of hydroxypropyl-β-cyclodextrin with novel cytotoxic compounds: Solubility and thermodynamic properties
Shehatta Cyclodextrins as enhancers of the aqueous solubility of the anthelmintic drug mebendazole: thermodynamic considerations
Bognanni et al. Exploring charged polymeric cyclodextrins for biomedical applications

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties